More on CGEM

- Summary
- Chart
- Profile
- Historical

Data

- Earnings (+24.3% Growth)
- Ratings (10.0 Score)

Upcoming Events

- Earnings (8/6/26)

News

- Analyst Ratings
- Earnings Related
- Guidance
- Insider Trades
- Mgmt Changes
- M & A
- Retail Sales
- Rumors
- Stock Buybacks
More...

Cullinan Therapeutics (NQ:CGEM)
Delayed: 15.21 -0.13 (0.85%)
Prev. Close $15.34  
Open$15.41 
52 Wk High$0.19 
52 Wk Low$0.03 
Day High$15.50 
Day Low$15.01 
P/E N/A  
EPS$0.00 
Volume909,027 


May 26, 2026 07:00 AM Cullinan Therapeutics to Host Immunology Day to Showcase Promising Initial Clinical Data in Autoimmune Diseases for CLN-978, a CD19 T Cell Engager, and Velinotamig, a BCMA T Cell Engager
May 19, 2026 07:01 AM Cullinan Therapeutics receives FDA orphan drug status for leukemia drug
May 19, 2026 07:00 AM Cullinan Therapeutics Receives FDA Orphan Drug Designation for CLN-049, a Novel FLT3xCD3 T Cell Engager, in Relapsed/Refractory Acute Myeloid Leukemia
May 19, 2026 06:51 AM Cullinan Oncology (CGEM) Reiterated at Buy by Stifel on CLN-978 Data
May 18, 2026 05:00 PM Cullinan Therapeutics to Present Initial Clinical Data for CLN-978 in Treatment-Refractory Rheumatoid Arthritis and Systemic Lupus Erythematosus at EULAR 2026 Congress
May 18, 2026 08:34 AM The Biology Came First.
May 7, 2026 07:10 AM Cullinan Oncology, Inc. (CGEM) Tops Q1 EPS by 8c
May 7, 2026 07:00 AM Cullinan Therapeutics Provides Corporate Update and Reports First Quarter 2026 Financial Results
May 6, 2026 05:01 PM Form 4 Cullinan Therapeutics, For: May 05 Filed by: Michaelson Jennifer
Apr 28, 2026 12:09 PM Cullinan Oncology Inc. (CGEM) PT Raised to $30 at H.C. Wainwright
View All Articles

Entities mentioned with CGEM

View All Entities